에 대한 최신 뉴스 Yum China Holdings (NYSE:YUMC) 주식

Yum China Holdings

With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.

Meta Platforms Inc. (META)

Equities

Large Cap

Movers

BURL

CRWV

NVDA

RDDT

SMCI

YUMC

유나이티드헬스, 메타 등 지난주 부활절 주간에 급락한 대형주 11종목 (4월 14~18일)

Prague,,Czech,Republic,08,27,2024:,Temu,App,Online,Marketplace

News

Topics

Trading Ideas

APTV

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

STLA

PDD홀딩스·알리바바 등 미중 무역 긴장 속 지난주 급락한 대형주 10종목: 4월 7일부터 11일까지 지난주 최악의 실적을 기록한 대형주는 다음과 같다.

PDD홀딩스·알리바바 등 미중 무역 긴장 속 지난주 급락한 대형주 10종목 (4월 7일~11일)

Tesla Inc. TSLA

BF/B

CVNA

Fomento Economico Mexicano S.A.B. De C.V.

KNSL

SOFI

TCOM

TSLA

이들 9개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 카바나(NYSE:CVNA)의 주가는 20.93% 급락했다. 공매도 업체인 힌덴버그 리서치의 비판적인 보고서는 Carvana의 회복을 &#34;신기루&#34;로 묘사하면서 약세 정서를 강화했다.

테슬라, 소파이 및 주류 주식이 지난주 최악의 성과를 보인 9개 대형주 중 일부 (12월 30일-1월 3일)

Yum China Holdings Inc

Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) has seen its stock climb 50% to $1.34 over the past week following a series of company announcements.
What To Know: The California-based electric vehicle maker recently <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">appointed</a> founder YT Jia as Co-CEO alongside current CEO Matthias Aydt, signaling a new dual-leadership structure. Jia will oversee finance, legal and supply chain operations in addition to his current responsibilities. His new equity incentive package is tied to market cap and stock performance.
At the company's recent "FF Stockholder Community and FX Co-Creation Day" in Los Angeles, Jia outlined strategic goals including launching the first FX model by end of 2025, achieving positive gross margin and operating cash flow and pursuing global AI and AIEV M&amp;A initiatives. 
California <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">political figures</a> including former Assembly Speaker Anthony Rendon and Hanford Mayor Lou Martinez expressed public support for the company's transformation efforts. 
Faraday Future emphasized its intent to maximize stakeholder value and resist illegal short-selling as it executes its Global Bridge Strategy.
Read Also: <a href="https://www.benzinga.com/news/25/04/45078865/d-wave-quantum-qbts-stock-falls-amid-valuation-critique-by-kerrisdale-capital">D-Wave Quantum Stock Falls Amid Valuation Critique By Kerrisdale Capital</a>
<h2 class="wp-block-heading">How To Buy FFAI Stock</h2>
By now you're likely curious about how to participate in the market for Faraday Future &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Faraday Future, which is trading at $1.33 as of publishing time, $100 would buy you 75.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FFAI has a 52-week high of and a 52-week low of

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future (FFAI) Shares Surge 50% Amid Leadership Changes And Strategic Updates

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2F&amp;esheet=54246103&amp;newsitemid=20250429590949&amp;lan=en-US&amp;anchor=BeiGene&amp;index=1&amp;md5=0c09798a0c67c852789b965c290809ae">BeiGene</a>, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.
On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA&#xAE; (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene's petition to institute the PGR. The USPTO's Final Written Decision is appealable by Pharmacyclics.
Commenting on the ruling, BeiGene General Counsel Chan Lee said: "We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today's decision reinforces our belief that Pharmacyclics' ‘803 patent is overly broad and invalid. BeiGene is confident in the strength of our intellectual property supporting BRUKINSA, a clearly differentiated and independently developed medicine. With approvals in more than 70 countries and regions for the treatment of multiple B-cell malignancies, BRUKINSA continues to set a new standard of care for patients worldwide."

USPTO Renders Final Decision, Invalidating All Challenged Pharmacyclics Patent Claims Against BeiGene

SoFi Technologies Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) stock price gained Tuesday after it reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45062395/sofi-reports-first-quarter-2025-with-record-net-revenue-of-772-million-record-member-and-product-g" rel="noreferrer noopener">first-quarter 2025</a> earnings on Tuesday. Here's a look at the&nbsp;key metrics from the quarter.
The company reported quarterly adjusted sales of $770.72 million, beating analyst estimates of $739.04 million. The company reported quarterly adjusted earnings of 6 cents per share, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating&nbsp;analyst estimates of</a> 4 cents per share.
Adjusted revenue rose 33% year-over-year. Financial services revenue increased by 101% year-over-year, lending segment revenue increased by 25% year-over-year, and technology platform revenue increased by 10% year-over-year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44989977/sofi-stock-is-up-11-this-week-whats-going-on" rel="noreferrer noopener">SoFi Stock Jumps as It Opens AI and Private Market Investments to Everyday Investors</a>
Net interest income of&nbsp;$498.7 million&nbsp;was up 24%&nbsp;year-over-year, driven by a&nbsp;23%&nbsp;growth in average interest-earning assets and an 82 basis points decrease in cost of funds.
SoFi added 800,000 new members in the quarter, bringing total members up to 10.9 million, up 34% year-over-year. Product additions totaled nearly 1.2 million in the quarter.
SoFi&nbsp;CEO&nbsp;Anthony Noto&nbsp;<a target="_blank" href="https://www.cnbc.com/2025/04/29/sofi-crypto-investing.html" rel="noreferrer noopener">told</a> CNBC in an interview Tuesday that the fintech bank will bring back cryptocurrency investing this year following a shift in the regulatory landscape under the Trump administration. It had to dump crypto investing in late 2023 to bag a bank charter.&nbsp;
Outlook: In the second quarter of 2025, SoFi expects to generate $785 million—$805 million of adjusted net revenue versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of</a> $783.02 million, $200 million—$210 million of adjusted EBITDA, $60 million—$70 million of GAAP net income and $0.05-$0.06 of GAAP EPS (below the estimate of $0.06).
For the full year 2025, the company expects adjusted net revenue of $3.235 billion-$3.310 billion (<a href="https://www.benzinga.com/25/01/43233747/sofi-q4-earnings-24-revenue-increase-adds-785k-members-ceo-highlights-strong-financial-services-momentum-projects-23-26-revenue-growth-for-2025" target="_blank" rel="noreferrer noopener">prior $3.200 billion-$3.275 billion</a>) versus analyst consensus of $3.200 billion, which equates to approximately 24%-27% (prior 23%-26%) year-over-year growth.
Sofi anticipates an adjusted EBITDA of $875 million-$895 million (prior $845 million-$865 million), GAAP net income of $320 million- $330 million (prior $285 million-$305 million), and GAAP EPS of $0.27-$0.28 (prior $0.25 to $0.27) versus consensus of $0.26. 
Price Action: SOFI stock is up 2.84% at $13.58 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in" target="_blank" rel="noreferrer noopener">Cramer Cautions on SoFi Stock After Weak 2025 Profit Outlook</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Guidance

Tech

SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback

Vacasa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) ("Vacasa" or the "Company"), a leading vacation rental management platform in North America, today announced that its stockholders have approved the proposed merger with Casago (the "Merger").
On April 29, 2025, Vacasa held a special meeting of the Company's stockholders (the "Special Meeting") to vote on a proposal (the "Merger Agreement Proposal") to adopt the Agreement and Plan of Merger, dated as of December 30, 2024, as amended by Amendment No. 1 thereto, dated as of March 17, 2025, and by Amendment No. 2 thereto, dated as of March 28, 2025. At the Special Meeting, approximately 69% of the Company's Class A common stock, 96% of the Company's Class B common stock and 72% of the Company's Class A common stock and Class B common stock, voting together as a single class, voted in favor of the Merger Agreement Proposal.
The Company expects closing of the Merger to occur at 11:59 pm ET on April 30, 2025, subject to the satisfaction or waiver of the remaining closing conditions.

VCSA

Vacasa Stockholders Approve Proposed Merger With Casago

Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares fell 13.2% to $12.85 during Tuesday&#8217;s session after the solar-grade polysilicon producer reported <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">worse-than-expected</a> first-quarter results, signaling possible industry struggles.
What To Know: The company posted an adjusted net loss of 80 cents per ADS, wider than analyst expectations of a 69 cent loss. Revenue dropped 70% year-over-year to $123.9 million, missing the $182.1 million consensus. The sharp decline was driven by lower sales volumes and weak pricing, amid persistent overcapacity and muted demand in the solar PV market.
Gross margin plunged to -65.8% from +17.4% a year ago, with a gross loss of $81.5 million. Polysilicon average selling prices dropped to $4.37/kg, below both production and cash costs. Despite losses, Daqo&#8217;s balance sheet shows $2.15 billion in liquid assets and <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">no financial debt</a>.
CEO Xiang Xu said the company ran at 33% capacity to manage inventory and mitigate low prices. Looking ahead, Daqo expects second-quarter polysilicon output of 25,000–28,000 MT. Management remains confident in long-term prospects, citing cost leadership, new technologies and China&#8217;s push for solar expansion.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45073201/plug-power-stock-is-trending-tuesday-whats-going-on">Plug Power Stock Is Trending Tuesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy DQ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Daqo New Energy&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DQ has a 52-week high of $30.85 and a 52-week low of $12.40.

Daqo New Energy (DQ) Stock Slides On Steep Revenue, Earnings Miss In Q1

Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/n45062385/the-sherwin-williams-company-reports-2025-first-quarter-financial-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $5.31 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $5.4 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $2.25, versus estimates of $2.16 per share</li>
</ul>
Sherwin-Williams said total sales declined 1.1% year-over-year. Consumer Brands Group sales fell 6% year-over-year, primarily due to &#8220;soft&#8221; DIY demand in North America. Performance Coating Group sales were down 4.8% in the quarter. Paint Stores Group sales fared better, seeing 1.2% sales growth during the period, primarily driven by selling price increases. 
The company returned&nbsp;$552.1 million&nbsp;to shareholders in the first quarter in the form of dividends and repurchases. Sherwin-Williams ended the period with $199.8 million in cash and cash equivalents.
&#8220;In a demand environment that remained choppy as we anticipated, Sherwin-Williams continued to execute our strategy and delivered solid&nbsp;first quarter&nbsp;results driven by gross margin expansion and good cost control,&#8221; said Heidi Petz, chair, president and CEO of Sherwin-Williams.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45061797/us-stock-futures-edge-higher-tuesday-expert-warns-of-perfect-volatility-storm-with-major-earnings-and-economic-data-due-this-week">US Stock Futures Edge Higher Tuesday: Expert Warns Of &#8216;Perfect Volatility Storm&#8217; With Major Earnings And Economic Data Due This Week</a>
Guidance: Sherwin-Williams expects second-quarter revenue to be up or down in the low-single digit percentage range. The company guided for full-year 2025 net sales growth in the low-single digit percentage range. 
Sherwin-Williams also expects full-year adjusted earnings of $11.65 to $12.05 per share versus estimates of $11.90 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;We continue to expect demand softness to persist in several end markets well into the second half of the year. Regarding current tariffs, it&#8217;s important to remember that the largest portion of our revenue is in&nbsp;the United States, and the majority of our raw materials are sourced in the regions where we manufacture. In a macro-economic environment that remains turbulent, we are focused on being a source of stability and reliability for our customers, providing them with differentiated solutions that increase their productivity and profitability,&#8221; Petz said.
SHW Price Action: <a href="http://benzinga.com/quote/SHW">Sherwin-Williams shares</a> were up 5.46% at $350.33 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Sherwin-Williams Reports Mixed Q1 Results In 'Choppy' Demand Environment

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">epidermolysis bullosa (RDEB)</a>.
RDEB is&nbsp;a severe, genetically inherited skin disorder characterized by blistering and skin fragility, often presenting at birth.
Zevaskyn is the only FDA-approved product to treat RDEB wounds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061116/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-p" rel="noreferrer noopener">with a single application</a>.
Zevaskyn consists of a patient&#8217;s skin cells (keratinocytes) genetically modified to produce functional Type VII collagen. Zevaskyn sheets are surgically applied to the patient&#8217;s wounded areas. In a single application, up to 12 credit card-sized sheets can be combined to cover large areas or applied to multiple distinct wounds, allowing for significant coverage of affected body areas.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Zevaskyn is expected to be available beginning in the third quarter of 2025 through Zevaskyn Qualified Treatment Centers.
The FDA approval is based on the pivotal Phase 3 VIITAL study, which met its two co-primary efficacy endpoints, demonstrating statistically significant healing of 50% or more from baseline in large chronic RDEB wounds and pain reduction from baseline as assessed by the Wong-Baker FACES scale, as evaluated at six months after treatment.
Across 43 large and chronic wounds treated with a single application of Zevaskyn, 81% of wounds showed 50% or more healing (P&lt;0.0001) as evaluated at six months, compared to 16% in 43 matched control wounds treated with standard-of-care.
The most common adverse events were observed in fewer than 5% of patients, including procedural pain and itch.
The Phase 1/2a study of Zevaskyn, which involved 38 chronic wounds across seven patients, showed that a single surgical application of Zevaskyn was associated with long-term improvement at treated sites over a median follow-up of 6.9 years, ranging from 4 to 8 years.
Last April, the FDA issued a Complete Response Letter (CRL) in response to the company&#8217;s Biologics License Application (BLA) for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38380100/fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink" rel="noreferrer noopener">pz-cel for RDEB</a>.&nbsp;
The FDA noted that certain additional information&nbsp;was needed&nbsp;to&nbsp;satisfy Chemistry Manufacturing and Controls (CMC) requirements.&nbsp;
Price Action: ABEO stock is up 2.34% at $5.46 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides</a></li>
</ul>
Photo via Shutterstock

Health Care

General

ABEO

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Sleep Number will report an earnings per share (EPS) of $-0.05. 
Investors in Sleep Number are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 41.89% drop in the share price the next day.
Here's a look at Sleep Number's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.17</td>
<td>-0.37</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.14</td>
<td>-0.22</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-42.0%</td>
<td>4.0%</td>
<td>20.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953405_0.png" alt="eps graph" />
<h3>Sleep Number Share Price Analysis</h3>
Shares of Sleep Number were trading at $7.4 as of April 28. Over the last 52-week period, shares are down 43.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SNBR/earnings">To track all earnings releases for Sleep Number visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNBR

Earnings Outlook For Sleep Number

Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Oatly Group to report an earnings per share (EPS) of $-0.84.
The market awaits Oatly Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $1.60, leading to a 37.69% increase in the share price on the subsequent day.
Here's a look at Oatly Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.4</td>
<td>-1.2</td>
<td>-1.4</td>
<td>-1.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3</td>
<td>-1.2</td>
<td>-1</td>
<td>-1.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>38.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953397_0.png" alt="eps graph" />
<h3>Tracking Oatly Group's Stock Performance</h3>
Shares of Oatly Group were trading at $10.0 as of April 28. Over the last 52-week period, shares are down 55.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OTLY/earnings">To track all earnings releases for Oatly Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OTLY

Oatly Group Earnings Preview

<ul>
<li>IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.</li>
<li>IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV.</li>
<li>IPH4502 showed strong preclinical activity across multiple tumor types, including triple-negative breast cancer, head and neck, and esophageal cancers, supporting its potential for broad clinical application.</li>
</ul>
Innate Pharma SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/IPH#PARIS">IPH</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

IPHA

PARIS:IPH

Innate Pharma Presents New Preclinical Data For IPH4502 AACR Annual Meeting 2025; IPH4502 Shows Strong Preclinical Activity Across Multiple Tumor Types

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Pulmonx will report an earnings per share (EPS) of $-0.40. 
Pulmonx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 32.23% increase in the share price on the following day.
Here's a look at Pulmonx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.45</td>
<td>-0.45</td>
<td>-0.42</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.36</td>
<td>-0.39</td>
<td>-0.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>32.0%</td>
<td>-8.0%</td>
<td>-6.0%</td>
<td>22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953386_0.png" alt="eps graph" />
<h3>Market Performance of Pulmonx's Stock</h3>
Shares of Pulmonx were trading at $5.19 as of April 28. Over the last 52-week period, shares are down 31.09%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LUNG/earnings">To track all earnings releases for Pulmonx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUNG

Pulmonx's Earnings Outlook

<ul>
<li>Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies</li>
</ul>

Events

ABCL

AbCellera Presents Data For Preclinical Efficacy Of PSMA x CD3 T-Cell Engagers At AACR 2025

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.09. 
Investors in Surmodics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 4.06% drop in the share price on the subsequent day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953377_0.png" alt="eps graph" />
<h3>Tracking Surmodics's Stock Performance</h3>
Shares of Surmodics were trading at $31.1 as of April 28. Over the last 52-week period, shares are down 7.53%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Surmodics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Surmodics.
With 1 analyst ratings, Surmodics has a consensus rating of Buy. The average one-year price target is $43.0, indicating a potential 38.26% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Treace Medical Concepts, with an average 1-year price target of $9.17, suggesting a potential 70.51% downside.</li>
<li>Analysts currently favor an Buy trajectory for ClearPoint Neuro, with an average 1-year price target of $25.0, suggesting a potential 19.61% downside.</li>
<li>Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $24.0, suggesting a potential 22.83% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surmodics</td>
<td>Buy</td>
<td>-2.06%</td>
<td>$13.56M</td>
<td>-3.17%</td>
</tr>
<tr>
<td>Treace Medical Concepts</td>
<td>Neutral</td>
<td>10.44%</td>
<td>$55.48M</td>
<td>-0.46%</td>
</tr>
<tr>
<td>ClearPoint Neuro</td>
<td>Buy</td>
<td>14.11%</td>
<td>$4.76M</td>
<td>-19.81%</td>
</tr>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>2701.48%</td>
<td>$12.97M</td>
<td>-8.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Surmodics ranks at the bottom for Revenue Growth and Gross Profit, with negative values compared to peers. However, it ranks at the top for Return on Equity, showing a positive performance in this metric. The Consensus rating for Surmodics is in line with one peer and higher than the other two.
<h3>Delving into Surmodics's Background</h3>
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
<h3>Unraveling the Financial Story of Surmodics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Surmodics's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Surmodics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surmodics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Surmodics's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SRDX

A Look at Surmodics's Upcoming Earnings Report

Standard Motor Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMP#NYSE">SMP</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Standard Motor Products to report an earnings per share (EPS) of $0.44.
The announcement from Standard Motor Products is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 0.38% drop in the share price on the subsequent day.
Here's a look at Standard Motor Products's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>1.11</td>
<td>0.78</td>
<td>0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.47</td>
<td>1.28</td>
<td>0.98</td>
<td>0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953361_0.png" alt="eps graph" />
<h3>Standard Motor Products Share Price Analysis</h3>
Shares of Standard Motor Products were trading at $23.94 as of April 28. Over the last 52-week period, shares are down 26.14%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMP/earnings">To track all earnings releases for Standard Motor Products visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Standard Motor Products's Quarterly Earnings

MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that MiMedx Group will report an earnings per share (EPS) of $0.05. 
MiMedx Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 1.62% increase in the share price the next day.
Here's a look at MiMedx Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.04</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.07</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>20.0%</td>
<td>-10.0%</td>
<td>19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953343_0.png" alt="eps graph" />
<h3>Tracking MiMedx Group's Stock Performance</h3>
Shares of MiMedx Group were trading at $6.83 as of April 28. Over the last 52-week period, shares are down 3.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on MiMedx Group</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MiMedx Group.
With 1 analyst ratings, MiMedx Group has a consensus rating of Outperform. The average one-year price target is $13.0, indicating a potential 90.34% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of CareDx, Vir Biotechnology and Iovance Biotherapeutics, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for CareDx, with an average 1-year price target of $30.33, suggesting a potential 344.07% upside.</li>
<li>Analysts currently favor an Buy trajectory for Vir Biotechnology, with an average 1-year price target of $58.2, suggesting a potential 752.12% upside.</li>
<li>Analysts currently favor an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $16.72, suggesting a potential 144.8% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for CareDx, Vir Biotechnology and Iovance Biotherapeutics, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiMedx Group</td>
<td>Outperform</td>
<td>7.00%</td>
<td>$76.00M</td>
<td>3.98%</td>
</tr>
<tr>
<td>CareDx</td>
<td>Buy</td>
<td>32.04%</td>
<td>$58.40M</td>
<td>23.94%</td>
</tr>
<tr>
<td>Vir Biotechnology</td>
<td>Buy</td>
<td>17.45%</td>
<td>$10.59M</td>
<td>-8.75%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>15189.21%</td>
<td>$28.15M</td>
<td>-10.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MiMedx Group ranks at the bottom for Revenue Growth and Gross Profit among its peers. However, it ranks at the top for Return on Equity.
<h3>Discovering MiMedx Group: A Closer Look</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, MiMedx Group showcased positive performance, achieving a revenue growth rate of 7.0% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: MiMedx Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MiMedx Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MiMedx Group's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MDXG/earnings">To track all earnings releases for MiMedx Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDXG

A Peek at MiMedx Group's Future Earnings

MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that MediaAlpha will report an earnings per share (EPS) of $0.35.
The announcement from MediaAlpha is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.36, leading to a 18.49% drop in the share price on the subsequent day.
Here's a look at MediaAlpha's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.12</td>
<td></td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.17</td>
<td>0.07</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-18.0%</td>
<td>-17.0%</td>
<td>13.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking MediaAlpha's Stock Performance</h3>
Shares of MediaAlpha were trading at $8.47 as of April 28. Over the last 52-week period, shares are down 58.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/MAX/earnings">To track all earnings releases for MediaAlpha visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: MediaAlpha's Earnings Outlook

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Matthews International to report an earnings per share (EPS) of $0.38.
The market awaits Matthews International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.08, leading to a 9.93% drop in the share price on the subsequent day.
Here's a look at Matthews International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.38</td>
<td>0.55</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.55</td>
<td>0.56</td>
<td>0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>21.0%</td>
<td>-5.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953327_0.png" alt="eps graph" />
<h3>Tracking Matthews International's Stock Performance</h3>
Shares of Matthews International were trading at $20.68 as of April 28. Over the last 52-week period, shares are down 19.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MATW/earnings">To track all earnings releases for Matthews International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MATW

Earnings Preview: Matthews International

OneSpaWorld Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate OneSpaWorld Holdings to report an earnings per share (EPS) of $0.21.
Anticipation surrounds OneSpaWorld Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.01 in the last quarter, leading to a 7.96% drop in the share price on the following day.
Here's a look at OneSpaWorld Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.23</td>
<td>0.2</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.20</td>
<td>0.26</td>
<td>0.2</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953305_0.png" alt="eps graph" />
<h3>Tracking OneSpaWorld Holdings's Stock Performance</h3>
Shares of OneSpaWorld Holdings were trading at $17.24 as of April 28. Over the last 52-week period, shares are up 21.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OSW/earnings">To track all earnings releases for OneSpaWorld Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of OneSpaWorld Holdings's Earnings

CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that CTS will report an earnings per share (EPS) of $0.49. 
The market awaits CTS's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 1.89% increase in the share price the following trading session.
Here's a look at CTS's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.57</td>
<td>0.53</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.63</td>
<td>0.54</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953298_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of CTS were trading at $39.8 as of April 28. Over the last 52-week period, shares are down 15.86%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/CTS/earnings">To track all earnings releases for CTS visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: CTS's Earnings Preview

Whales with a lot of money to spend have taken a noticeably bearish stance on BlackRock.
Looking at options history for BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $208,293 and 2, calls, for a total amount of $59,300.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $810.0 to $1000.0 for BlackRock over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for BlackRock's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of BlackRock's whale trades within a strike price range from $810.0 to $1000.0 in the last 30 days. 
<h3>BlackRock Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745953296_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$105.0</td>
<td>$100.0</td>
<td>$105.0</td>
<td>$900.00</td>
<td>$52.5K</td>
<td align="right">2</td>
<td align="right">5</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$20.4</td>
<td>$14.4</td>
<td>$17.4</td>
<td>$810.00</td>
<td>$34.8K</td>
<td align="right">314</td>
<td align="right">20</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$83.9</td>
<td>$83.8</td>
<td>$83.8</td>
<td>$920.00</td>
<td>$33.5K</td>
<td align="right">70</td>
<td align="right">7</td>
</tr>
<tr>
<td>BLK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$37.5</td>
<td>$32.3</td>
<td>$32.3</td>
<td>$1000.00</td>
<td>$32.3K</td>
<td align="right">5</td>
<td align="right">30</td>
</tr>
<tr>
<td>BLK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$75.9</td>
<td>$73.7</td>
<td>$75.9</td>
<td>$900.00</td>
<td>$30.3K</td>
<td align="right">61</td>
<td align="right">12</td>
</tr>
</tbody>
</table>

<h3>About BlackRock</h3>
BlackRock is the largest asset manager in the world, with $11.584 trillion in assets under management at the end of March 2025. Its product mix is diverse, with 53% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 8% in money market funds, and 4% in alternatives. Passive strategies account for two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
In light of the recent options history for BlackRock, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>BlackRock's Current Market Status</h3>
<ul>
<li>With a volume of 176,614, the price of BLK is up 0.52% at $918.45. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About BlackRock</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1083.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on BlackRock with a target price of $1124. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on BlackRock with a target price of $1046. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for BlackRock, targeting a price of $1035. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for BlackRock, targeting a price of $1032. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on BlackRock, maintaining a target price of $1178. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for BlackRock with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

This Is What Whales Are Betting On BlackRock

Press Releases

Yum China Announces US$360 million Share Repurchase Agreements for First Half of 2025 as Part of Broader Capital Return Plan

Yum China Leads the Restaurant & Leisure Facilities Industry for the Fifth Consecutive Year on the Dow Jones Sustainability Index

Yum China to Report Fourth Quarter and Fiscal Year 2024 Financial Results

Yum China named as a "Top Employer" in China by Top Employers Institute for seventh consecutive year, achieving Top 2 national ranking

Dividends

Yum China Announces Disclosure under Hong Kong Stock Exchange Rules in Relation to a Possible Quarterly Dividend

Yum China Reports Fourth Quarter Results and Increases Dividend by 50%

Yum China Appoints Adrian Ding as Chief Financial Officer

2024 Sustainability Report Showcases Yum China's Consistent Commitment to ESG

Yum China to Report First Quarter 2025 Financial Results

Arcos Dorados Holdings Inc. Class A Shares

Arcos Dorados Holdings

Aramark

Biglari Holdings Inc. Class B Common Stock

Biglari Holdings

BJ's Restaurants

Dutch Bros

The Cheesecake Factory Incorporated - Common Stock

Cheesecake Factory

Cava Group

Cracker Barrel Old Country Store, Inc. - Common Stock

Cracker Barrel Old

Chipotle Mexican Grill, Inc. Common Stock

Chipotle Mexican Grill

DoorDash

Domino's Pizza

Darden Restaurants

Brinker International

First Watch Restaurant Group, Inc. - Common Stock

First Watch Restaurant Gr

SUPER HI INTERNATIONAL HOLDING LTD. - American Depositary Shares

Super Hi International

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA

McDonald's

Papa John's International, Inc. - Common Stock

Papa John's International

Starbucks

Sweetgreen

Shake Shack

Texas Roadhouse

Wendy's

Wingstop

Yum Brands

JP Morgan

Macquarie

HSBC

Deutsche Bank

지난주 성과가 가장 부진했던 대형주는 다음과 같다.
<ol>
<li>유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) 주가는 회사가 예상보다 저조한 1분기 실적을 발표하고 2025회계연도 조정 <a href="https://www.benzinga.com//node/44860240" target="_blank" rel="noreferrer noopener">EPS 가이드를 하향 조정한 후 23.60% 하락했다</a>.</li>
<li>글로벌 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) 주가는 회사가 <a href="https://www.benzinga.com//node/44862867" target="_blank" rel="noreferrer noopener">월드페이(Worldpay)의 지분을 66억 달러에 인수했다고 발표한 후 16.55% 하락했다</a>.</li>
<li>앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주가는 골드만 삭스(Goldman Sachs)의 애널리스트 에릭 셰리단이 <a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 500달러에서 335달러로 하향 조정한 후 9.71% 하락했다</a>.</li>
<li>휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) 주가는 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)이 예상보다 안 좋은 <a href="https://www.benzinga.com//node/44860240" target="_blank" rel="noreferrer noopener">1분기 실적을 발표한 후 8.88% 하락했다</a>.</li>
<li>다비타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>)의 주가는 지난 주 8.69% 하락했다.</li>
<li>메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)의 주가는 <a href="https://www.benzinga.com//node/44821791" target="_blank" rel="noreferrer noopener">FTC 반독점 재판 중에 8.20% 하락했다</a>. 여러 애널리스트가 <a href="https://www.benzinga.com/quote/meta/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 하향 조정했다</a>.</li>
<li>염 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주가는 7.70% 급락했다.</li>
<li>코어위브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>)의 주가는 7.37% 하락했다.</li>
<li>벌링턴 스토어스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>)의 주가는 연준 의장 파월이 경제 클럽에서 발언한 후 전반적인 시장 약세 속에서 6.97% 하락했다.</li>
<li>슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주가는 JP 모건 애널리스트 새믹 채터지가 <a href="https://www.benzinga.com/quote/smci/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 45달러에서 39달러로 하향 조정한 후 6.46% 하락했다</a>.</li>
<li>글로벌파운드리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) 주가는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)에서 미국 정부가 최근에 중국에 칩을 수출하기 위해 <a href="https://www.benzinga.com//node/44856114" target="_blank" rel="noreferrer noopener">면허가 필요하다고 통보했다고 발표한 후 6.24% 하락했다</a>.</li>
</ol>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

4월 7일부터 11일까지 지난주 최악의 실적을 기록한 대형주는 다음과 같다.
<ol>
<li>PDD홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) 주가는 13.16% 급락했다. 도널드 트럼프 대통령이 외국 이커머스 회사들이 <a href="https://www.benzinga.com//node/44714336" target="_blank" rel="noreferrer noopener">(800달러 이하의) 저렴한 패키지를 미국으로 무관세로 배송할 수 있게 해주던 소액 면세(de minimis) 기준을 폐지</a>했다.</li>
<li>페트롤레오 브라질레이로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) 주가는 11.96% 하락했다. 트럼프 대통령의 관세 유예 발표 이후 주식들이 급등한 뒤 조정을 받았다.</li>
<li>카맥스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) 주가는 9.72% 급락했다. 회사가 4분기<a href="https://www.benzinga.com//node/44733776" target="_blank" rel="noreferrer noopener"> 실적을 발표했지만 EPS 추정치를 밑돌았다.</a> 여러 애널리스트들이<a href="https://www.benzinga.com/quote/kmx/analyst-ratings" target="_blank" rel="noreferrer noopener"> 주가 전망치를 하향 조정</a>했다.</li>
<li>앱티브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) 주가는 9.58% 하락했다. UBS 애널리스트 조셉 스팍이 매수에서 중립으로 등급을 하향 조정하고 <a href="https://www.benzinga.com/quote/aptv/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 91달러에서 58달러</a>로 낮췄다.</li>
<li>스텔란티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) 주가는 8.74% 하락했다. 회사가 1분기 동안 출하량이 전년 대비 9% 감소하여 약<a href="https://www.benzinga.com//node/44763932" target="_blank" rel="noreferrer noopener"> 120만 대에 이르렀다고 발표</a>했다.</li>
<li>코어위브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) 주가는 8.51% 급락했다.</li>
<li>브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) 주가는 8.30% 하락했다. 트럼프 대통령이 자신의 집무실에서 기자들과의 대화 중<a href="https://www.benzinga.com//node/44756157" target="_blank" rel="noreferrer noopener"> 제약사들이 관세에 직면할 것이라고 확인</a>했다.</li>
<li>질로우 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) 주가는 8.09% 하락했다. 이는 미국-중국 무역 긴장 속에서 전체 시장이 반전되었기 때문이다. 30년 모기지 금리의 변동성도 주택 수요에 영향을 미칠 수 있다.</li>
<li>알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) 주가는 7.56% 하락했다. 미국과 중국 간의 무역 긴장이 격화되면서 이커머스<a href="https://www.benzinga.com//node/44704439" target="_blank" rel="noreferrer noopener"> 거대 기업의 국제 비즈니스 모델을 위협</a>하고 있다.</li>
<li>염 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) 주가는 지난주 7.37% 하락했다. 이는 미국-중국 무역 발표와 전체 시장 약세가 영향을 미쳤다.</li>
</ol>
사진 제공: Paulm1993 via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 9개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)의 주가는 20.93% 급락했다. 공매도 업체인 힌덴버그 리서치의 비판적인 보고서는 <a href="https://www.benzinga.com//node/42784518" target="_blank" rel="noreferrer noopener">Carvana의 회복을 &#8220;신기루&#8221;</a>로 묘사하면서 약세 정서를 강화했다.
2. 소파이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)의 주식은 키프, 브루옛 &amp; 우즈(Keefe, Bruyette and Woods)가 <a href="https://www.benzinga.com/quote/SOfi/analyst-ratings" target="_blank" rel="noreferrer noopener">시장 수행에서 언더퍼폼으로 하향 조정</a>한 후 10.60% 하락했다.
3. 얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주식은 10.40% 하락했다.
4. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 회사가 4분기 <a href="https://www.benzinga.com//node/42766117" target="_blank" rel="noreferrer noopener">생산 및 인도 수치</a>를 발표한 후 9.62% 급락했다. 애널리스트들은 주식에 대한 <a href="https://www.benzinga.com//node/42786667" target="_blank" rel="noreferrer noopener">가격 예측</a>을 수정했다.
5. 킨세일 캐피털 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>)의 주식은 JP 모건이 주식의 목표 가격을 <a href="https://www.benzinga.com/quote/knsl/analyst-ratings" target="_blank" rel="noreferrer noopener">$415에서 $412로 하향 조정</a>한 후 9.45% 하락했다.
6. 브라운 포먼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>)의 주식은 미국 총기 건강 책임자 머시가 알코올 소비가 암 위험을 증가시킬 수 있다는 경고를 발표한 후 8.20% 하락했다.
7. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 씨티그룹이 주식의 가격 예측을 <a href="https://www.benzinga.com/quote/tcom/analyst-ratings" target="_blank" rel="noreferrer noopener">$73에서 $78로 상향 조정</a>한 후 7.47% 하락했다.
8. 포멘토 이코노미코 멕시카노 S.A.B. de C.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>)의 주식은 미국 공중보건국장인 비벡 머시(Vivek Murthy)가 알코올 소비와 관련된 암 위험 증가에 대해 경고한 후 7.47% 하락했다.
9. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주식은 9.47% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%AA%A8%EB%B9%8C%EC%95%84%EC%9D%B4-%EB%B0%8F-arm%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">리비안, 모빌아이 및 Arm은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 30일-1월 3일)</a></li>
</ul>
이미지 출처: Tesla
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포와 탐욕 지수(CNN Money Fear and Greed index)가 전체 시장 심리가 하락했음을 보여주었고, 월요일에는 &#8220;공포&#8221; 구역에 머물렀다.
월요일에 미국 주식은 하락세로 마감했다. 다우존스 지수는 250포인트 이상 하락하면서 투자자들이 중요한 대통령 선거를 대비하는 모습이 나타났다.
경제 지표 측면에서, 미국의 공장 주문이 전월 대비 0.5% 감소하여 9월에 5,842억 달러로 집계되었다. 이는 수정된 8월의 0.8% 감소와 비교된다.
얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주가는 회사가 예상보다 좋은 3분기 EPS와 매출을 발표한 후 월요일에 7% 이상 상승했다.
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 주가는 연초 대비 약 182% 상승하고, 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 주가는 올해 가치가 절반 이상 하락했다.
대부분의 S&amp;P 500 섹터가 부정적인 마감세를 보였으며, 공공 서비스, 통신 서비스 및 금융 주식이 월요일에 가장 큰 손실을 기록했습니다. 그러나 에너지와 부동산 주식은 전체 시장 추세와 반대로 상승하여 세션을 마감했습니다.
다우 존스는 월요일에 약 258포인트 하락하여 41,794.60으로 마감했습니다. S&amp;P 500은 0.28% 하락하여 5,712.69로, 나스닥 종합지수는 0.33% 하락하여 18,179.98로 월요일 세션을 마감했습니다.
투자자들은 아처 대니얼스 미들랜드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), 얌 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) 및 커민스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)의 실적 발표를 기다리고 있다.
CNN 비즈니스 공포와 탐욕 지수란 무엇인가요?
현재 42.9의 지수는 월요일에 &#8220;공포&#8221; 구역에 남아 있었으며, 이전 지수는 44.5였다.
공포와 탐욕 지수는 현재 시장 심리를 측정한 것이다. 이는 높은 공포가 주가에 하락 압력을 가하고, 높은 탐욕이 그 반대의 효과를 미친다는 전제에 기반한다. 이 지수는 7개의 동등 가중 지표를 기반으로 계산된다. 지수는 0에서 100까지 범위가 있으며, 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">이번 달에 급락 가능성이 있는 상위 4개 기술 및 통신 주식</a></li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Pre-Market Outlook

INTC

투자자들이 美 대선을 대비하며 다우존스 지수가 250포인트 하락, '탐욕 지수'는 '공포' 영역에

지난주, 중국 중앙은행이 은행의 지급준비율(RRR)을 50bp(베이시스 포인트) 또는 0.5%포인트 인하하기로 발표하면서 미국에 상장된 중국 기업들의 <a href="https://www.benzinga.com//node/41065178" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가가 전반적으로</a> 상승했다.
지난주 가장 좋은 성과를 보인 10개의 대형 주식이 있다. 여러분의 포트폴리오에 포함되어 있나요?
1. JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주식은 중국 인민은행이 은행들이 보유해야 하는 현금의 양을 줄이기로 발표하고 <a href="https://www.benzinga.com//node/41062614" target="_blank" rel="noreferrer noopener">부동산 시장 지원 계획</a>을 발표한 후 39.75% 급등했다.
2. KE 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>)의 주식은 중국이 부양책의 일환으로 최대 2,840억 달러의 국채를 발행할 것이라는 보도가 나온 후 39.18% 상승했다.
3. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 중국이 부양책의 일환으로 최대 2,840억 달러의 <a href="https://www.benzinga.com//node/41026720" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">국채를 발행할 것</a>이라는 보도가 나온 후 35.52% 상승했다.
4. 리버티 브로드밴드 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41015233" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">차터 커뮤니케이션즈</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>)의 특별위원회에 반대 제안을 전달했다고 발표한 후 31.74% 상승했다.
5. 염 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)의 주식은 중국의 부책 발표로 인해 27.64% 상승했다.
6. H 월드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>)의 주식은 중국 주식의 핀 액션으로 인해 26.43% 상승했다.
7. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 중국 주식의 핀 액션으로 인해 지난 주 26.02% 상승했다.
8. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식은 정부의 부양책 발표로 인해 중국 주식의 랠리에 동참하면서 23.48% 상승했다.
9. 윈 리조트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>)의 주식은 모건 스탠리가 중립에서 비중 확대 등급으로 상향 조정하고 목표 주가를 97달러에서 104달러로 <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정</a>한 후 22.47% 상승했다.
10. 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)의 주식은 정부의 부양책 발표로 인해 중국 주식의 랠리에 동참하면서 21.95% 상승했다.
알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)와 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)도 지난주 중국 주식의 랠리에 동참하여 각각 20% 이상 상승했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EC%A0%9C%EB%84%A4%EB%A1%A0%EA%B3%BC-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">리제네론 파마, 슈퍼 마이크로 컴퓨터 및 글로벌 페이먼츠는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 23일-9월 27일)</a></li>
</ul>
Photo by Eric Prouzet on Unsplash
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Emerging Markets

BEKE

BIDU

CHTR

HTHT

LBRDA

WYNN

중국 주식 우세 - JD닷컴과 PDD는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 23일-9월 27일)

글로벌 시장은 극심한 변동성을 겪고 있으며, <a href="https://www.benzinga.com/markets/equities/24/08/40152271/mohamed-el-erian-grant-cardone-and-matt-weller-warn-of-deepening-global-market-selloff-as-yen-ri" target="_blank" rel="noopener" data-google-interstitial="false">일본의 닛케이 225 지수가 밤새 13% 급락한</a> 이후 월스트리트의 블랙 먼데이는 불가피한 것처럼 보였지만, 주가 지수는 뉴욕 정오 거래를 통해 장 초반 손실을 제한하려고 시도하고 있다.
이 변곡점은 7월의 서비스 부문 활동 조사에서 6월보다 개선된 여건과 예상보다 강한 확장세를 보여 미국 <a href="https://www.benzinga.com/news/econ-s/24/08/40161832/us-services-activity-returns-to-growth-in-july-global-market-selloff-stalls-are-recession-fears-over" target="_blank" rel="noopener" data-google-interstitial="false">경기 침체</a>에 대한 우려가 완화된 이후에 발생했다.
7월에는 ISM 서비스 구매관리자지수(PMI)가 48.8%에서 51.4%로 상승해 예상치인 51% 상승을 뛰어넘는 등 미국 서비스 부문의 기업 심리가 다시 확장세를 보였다.
ISM 데이터가 발표되기 전에 트레이더들은 오스탄 굴스비 시카고 연준 총재가 CNBC 인터뷰에서 모든 것이 논의될 수 있다고 말한 후 회의 중 연준 금리 인하를 추측했다.
이후 이 데이터가 발표되자, CME 그룹의 페드워치(FedWatch) 도구에 따르면 시장에 내재된 50베이시스포인트(bp) 금리 인하 가능성은 100%에서 약 80%로 감소한 반면, 25bp 인하 가능성은 약 0%에서 20%로 증가했다. .
S&amp;P 500은 4% 이상 하락한 5,120포인트에서 개장한 후 오후 12시 30분까지 손실폭을 소폭 줄인 5,233포인트에 거래되었다. 이는 전 날에 비해 2.1% 하락한 것이다.
기술주 중심의 나스닥 100, 다우존스가 추적하는 우량주 그리고 소형주에서도 비슷한 움직임이 관찰되었다.
금리 확률이 바뀌면서 채권 상승이 멈췄고 국채 수익률은 모든 만기에서 상승했다. 2년 만기 국채 수익률은 거래시간 초반 3.65%까지 하락한 뒤 4bp 오른 3.92%에 거래됐다.
인기 있는 iShares 20+Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 7회 연속 상승세를 보인 이후 변동이 없었다.
비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)은 뉴욕에서 오전 9시 30분에 처음으로 15% 하락했지만, 이후 오전 9시 30분부터 오후 12시 30분까지 10% 반등하여 일일 손실률을 5.9%로 줄였다.
원자재는 금과 석유가 각각 1.5%, 1.3% 하락하는 등 전반적으로 하락세를 보였다. 은은 두 달 만에 최악의 세션으로 거의 5% 급락했다.
<h2 class="wp-block-heading">월요일 주요 미국 지수 및 ETF</h2>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>1일 변동률</td>
</tr>
<tr>
<td>다우존스</td>
<td>38,918.07</td>
<td>-2.1 %</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>18,040.81</td>
<td>-2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,226.62</td>
<td>-2.2%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>2,055.96</td>
<td>-2.4%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">동부 표준시 12시 43분 기준 업데이트됨</figcaption></figure>
Benzinga Pro의 데이터에 따르면:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 520.50달러로 2.2% 하락했다.</li>
<li>SPDR Dow Jones Industrial Average(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)는 388.75달러로 2.1% 하락했다.</li>
<li>기술주 중심의 Invesco QQQ Trust Series(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 438.40달러로 2.3% 하락했다.</li>
<li>iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)는 203.26달러로 2.7% 하락했다.</li>
<li>부문별로는, Real Estate Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)가 1.2% 감소로 가장 작은 하락세를 보인 반면, Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 2.8% 하락하여 가장 큰 하락세를 보였다.</li>
</ul>
<h2 class="wp-block-heading">월요일의 개별 종목 움직임</h2>
<ul>
<li>켈라노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)의 주가는 비공개 기업인 마즈(Mars)가 프링글스(Pringles) 제조업체를 인수하기 위한 사전 협상을 진행 중이라고 월스트리트 저널(WSJ)이 보도한 후 14% 이상 급등했다.</li>
</ul>
실적에 대한 반응으로 움직인 주식들은 다음과 같다:
<ul>
<li>바이오엔텍 SE(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) (2.54% 하락),</li>
<li>칼라일 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) (8% 하락),</li>
<li>타이슨 푸드(NYSW:TSN) (4% 상승)</li>
</ul>
마감 이후에 실적 발표는은 다음과 같다: 애드트랜 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>), AVIS 버짓 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>), 다이아몬드백 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), CSX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), 나비타스 반도체(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), J&amp;J 스낵 푸드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>), 팔란티어 테크놀로지스NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 및 염 차이나 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NASDAQ">YUMC</a>).
Photo: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Cryptocurrency

Macro Economic Events

Mid Cap

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Small Cap

Treasuries

Econ #s

Economics

Federal Reserve

ETFs

$BTC

ADTN

BNTX

FANG

JJSF

NVTS

PLTR

XLRE

미국 주식 시장은 서비스 지표의 확장에 블랙 먼데이의 하락을 축소, 채권 상승은 정체

화요일 오전 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 코카콜라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)가 개장 전에 102억 9천만 달러의 매출과 주당 65센트의 분기 이익을 보고할 것으로 예상하고 있다. 코카콜라 주가는 시간외 거래에서 0.2% 하락한 61.95달러를 기록했다.</li>
<li>얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)는 1분기에 긍정적인 이익을 발표했지만 매출은 기대에 못 미쳤다. 얌 차이나 주가는 시간외 거래에서 3.4% 하락한 38.70달러를 기록했다.</li>
<li>분석가들은맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>)가 57억 5천만 달러의 매출과 주당 이익으로 2.54달러로 기록할 것으로 예상하고 있다. 회사는 시장 개장 전에 시적을 발표할 예정이다. 맥도날드 주가는 시간외 거래에서 0.2% 상승한 274.00달러를 기록했다.</li>
</ul>
저희의 <a href="https://www.benzinga.com/premarket/">개장 전 시장 뉴스를 확인하세요</a>
<ul>
<li>센사타 테크놀러지스 홀딩(NYSE:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>)는 월요일 1분기에 예상보다 강한 결과를 보고했다. 회사는 제프 코트(Jeff Cote)가 CEO 겸 사장직을 은퇴할 것이라고 말했다. 센사타는 2분기 조정 수익이 주당 89~95센트, 매출 10억 2,500만~10억 5,500만 달러가 될 것으로 예상한다고 밝혔다. 센사타의 주가는 시간외 거래에서 17.6% 상승한 42.05달러를 기록했다.</li>
<li>분석가들은 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)이 시장 마감 후 1,331억 달러의 매출과 주당 77센트의 분기 이익을 기록할 것으로 예상한다. 아마존 주가는 시간외 거래에서 0.7% 상승한 182.26달러를 기록했다.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38509641/mcdonalds-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-street">맥도날드, Q1 매출 확대 예상… 월스트리트 최고의 분석가들의 최신 예측 변화</a>

AMZN

코카콜라, 아마존 그리고 화요일 주목해야 할 주식 3종목

월요일 아침 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
벤징가 프로의 데이터에 따르면 월스트리트는 도미노 피자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>)가 개장 전 매출 10억 8천만 달러, 주당 3.39달러의 분기 이익을 보고할 것으로 예상하고 있다. 도미노의 주가는 시간 외 거래에서 0.3% 상승한 500.39달러를 기록했다.
분석가들은 얌 차이나 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>)가 30억 5천만 달러의 매출과 주당 65센트의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 수익을 발표할 예정이다. 얌 차이나의 주가는 시간 외 거래에서 0.7% 상승한 39.91달러를 기록했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 EV 판매 및 마진 하락에 따른 비용 절감을 위해 이달 초 회사가 발표한 10% 정리해고의 일환으로 네바다 시설에서 직원 693명을 해고할 예정인 것으로 알려졌다. 이 회사는 또한 출시 불과 며칠 만에 미국에서 새로운 모델 3 퍼포먼스의 가격을 1,000달러 인상했다. 테슬라 주가는 시간 외 거래에서 0.4% 상승한 168.93달러를 기록했다.
시장이 개장하기 전에 온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)은 매출 18억 5천만 달러, 주당 1.04달러의 분기 이익을 보고할 것으로 예상된다. 온 세미컨덕터의 주가는 시간 외 거래에서 0.7% 상승한 68.50달러를 기록했다.
분석가들은 NXP 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>)가 마감 후 31억 3천만 달러의 매출과 31억 3천만 달러의 분기 이익을 주당 3.16달러로 기록할 것으로 예상된다. NXP 반도체 주가는 시간외 거래에서 0.5% 상승한 243.80달러를 기록했다.

Comments

Yum China Holdings

뉴스

에 대한 최신 뉴스 Yum China Holdings (NYSE:YUMC) 주식

일요일, 4월 20, 2025

일요일, 4월 13, 2025

일요일, 1월 05, 2025

화요일, 11월 05, 2024

일요일, 9월 29, 2024

월요일, 8월 05, 2024

화요일, 4월 30, 2024

월요일, 4월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌